特発性肺線維症(IPF)治療薬の世界市場2016-2020

◆英語タイトル:Global Idiopathic Pulmonary Fibrosis 2016-2020
◆商品コード:IRTNTR8081
◆発行会社(調査会社):Technavio
◆発行日:2016年5月5日
◆ページ数:60
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD2,500 ⇒換算¥285,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥342,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥456,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、特発性肺線維症(IPF)治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、疾患概要、特発性肺線維症(IPF)治療薬の世界市場規模及び予測、薬剤種類別分析、市場シェア、地域別分析/市場規模、市場の成長要因、市場の課題、製品パイプライン分析、市場動向、競争状況などの情報をお届けいたします。
【レポートの概要】

About Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis belongs to a group of lung diseases known as interstitial lung diseases. It affects people in the age group 50-70 years. Diagnosis is effected by the exclusion of other interstitial lung diseases. High-resolution computed tomography (CT) is often employed to confirm the presence of the disease. There is no permanent cure for this disease; therefore, treatment involves relieving underlying symptoms. Nintedanib and pirfenidone are the two approved drugs for the treatment of idiopathic pulmonary fibrosis. Corticosteroids and immunosuppressive drugs are also used for the treatment.

Technavio’s analysts forecast the global idiopathic pulmonary fibrosis market to grow at a CAGR of 23.97% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global idiopathic pulmonary fibrosis market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of prescription, generic, and off-label drugs used in the treatment of idiopathic pulmonary fibrosis.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Idiopathic Pulmonary Fibrosis Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Baxter International
• Boehringer Ingelheim
• F.Hoffmann-La Roche
• Prometheus Laboratories

[Other prominent vendors]
• Afferent Pharmaceuticals
• Amgen
• Biogen
• Bristol-Myers Squibb
• Cipla
• FibroGen
• Gilead Sciences
• GlaxoSmithKline
• GNI Group
• Horizon Pharma
• ImmuneWorks
• MediciNova
• MedImmune (subsidiary of AstraZeneca)
• Novartis
• Pfizer
• Promedior
• ProMetic Life Sciences
• Sanofi
• Shionogi
• Zai Lab

[Market driver]
• Unmet medical need
• For a full, detailed list, view our report

[Market challenge]
• Lack of proper diagnosis
• For a full, detailed list, view our report

[Market trend]
• Patient assistance programs
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Disease overview
• Understanding the disease
• Pathogenesis
• Signs and symptoms
• Diagnosis
• Management
• Epidemiology

PART 06: Pipeline analysis
• Lebrikizumab
• Tipelukast
• Tralokinumab
• FG-3019
• Simtuzumab
• BMS-986020
• AF-219
• SAR156597
• BG00011
• PRM-151
• PBI-4050

PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 08: Market segmentation by ROA
• Oral
• Parenteral

PART 09: Market segmentation by drug class
• Systemic corticosteroids
• Immunosuppressants
• Tyrosine kinase inhibitors
• Anti-fibrotic agents

PART 10: Geographical segmentation
• Global idiopathic pulmonary fibrosis market by geographical segmentation 2015-2020
• Idiopathic pulmonary fibrosis market in Americas
• Idiopathic pulmonary fibrosis market in EMEA
• Idiopathic pulmonary fibrosis market in APAC

PART 11: Market drivers
• Special regulatory designations for pipeline candidates
• Growth in patient population
• Unmet medical needs

PART 12: Impact of drivers

PART 13: Market challenges
• Unknown disease etiology
• Lack of proper diagnosis
• Increased use of off-label and alternative therapies

PART 14: Impact of drivers and challenges

PART 15: Market trends
• Patient assistance programs
• Increase in M&A
• Rise in public awareness

PART 16: Vendor landscape
• Competitive scenario
• Market share analysis 2015
• Baxter International
• Boehringer Ingelheim
• F Hoffmann-La Roche
• Prometheus Laboratories
• Other prominent vendors

PART 17: Appendix
• List of abbreviations

PART 18: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Common symptoms of idiopathic pulmonary fibrosis
Exhibit 03: Other signs and symptoms of idiopathic pulmonary fibrosis
Exhibit 04: Treatment options for idiopathic pulmonary fibrosis
Exhibit 05: Drugs used in the treatment of idiopathic pulmonary fibrosis
Exhibit 06: Global idiopathic pulmonary fibrosis market: Pipeline portfolio
Exhibit 07: Global idiopathic pulmonary fibrosis market 2015-2020 ($ billions)
Exhibit 08: Five forces analysis
Exhibit 09: Segmentation of global idiopathic pulmonary fibrosis drugs market by ROA
Exhibit 10: Global idiopathic pulmonary fibrosis drugs market segment by drug class
Exhibit 11: Global idiopathic pulmonary fibrosis market segmentation by geography 2015
Exhibit 12: Idiopathic pulmonary fibrosis market revenue by geography 2015-2020 ($ millions)
Exhibit 13: Idiopathic pulmonary fibrosis market in Americas 2015-2020 ($ millions)
Exhibit 14: Idiopathic pulmonary fibrosis market in EMEA 2015-2020 ($ millions)
Exhibit 15: Idiopathic pulmonary fibrosis market in APAC 2015-2020 ($ millions)
Exhibit 16: Key drivers
Exhibit 17: Impact of drivers
Exhibit 18: Key challenges
Exhibit 19: Impact of drivers and challenges
Exhibit 20: Key trends
Exhibit 21: Baxter International: Business segmentation by revenue 2014
Exhibit 22: Baxter International: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 23: Baxter International: Geographical segmentation by revenue 2014
Exhibit 24: Baxter International: Key takeaways
Exhibit 25: Boehringer Ingelheim: Business segmentation by revenue 2014
Exhibit 26: Boehringer Ingelheim: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 27: Boehringer Ingelheim: Geographical segmentation by revenue 2014
Exhibit 28: Boehringer Ingelheim: Key takeaways
Exhibit 29: F Hoffmann-La Roche: Business segmentation 2014 by revenue
Exhibit 30: F Hoffmann-La Roche: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 31: F Hoffmann-La Roche: Geographical segmentation by revenue 2014
Exhibit 32: F Hoffmann-La Roche: YoY growth and revenue generated from CellCept 2011-2014 ($ millions)
Exhibit 33: F.Hoffmann-La Roche: Key takeaways
Exhibit 34: Prometheus Laboratories: Product categories
Exhibit 35: Prometheus Laboratories: Key takeaways



【掲載企業】

Baxter International, Boehringer Ingelheim, F.Hoffmann-La Roche, Prometheus Laboratories, Afferent Pharmaceuticals, Amgen, Biogen, Bristol-Myers Squibb, Cipla, FibroGen, Gilead Sciences, GlaxoSmithKline, GNI Group, Horizon Pharma, ImmuneWorks, MediciNova, MedImmune (subsidiary of AstraZeneca), Novartis, Pfizer, Promedior, ProMetic Life Sciences, Sanofi, Shionogi, Zai Lab.

【レポートのキーワード】

特発性肺線維症(IPF)、特発性肺線維症治療薬、製薬、医薬品、パイプライン、副腎皮質ステロイド、免疫抑制剤、チロシンキナーゼ阻害薬

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[特発性肺線維症(IPF)治療薬の世界市場2016-2020]販売に関する免責事項
★調査レポート[特発性肺線維症(IPF)治療薬の世界市場2016-2020]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆